M&A / Deals Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Pharmaceutical TechnologyWhether the deal reaches its full value hinges on US regulatory milestones for Centessa's lead candidate, cleminorexton.M&A / DealsNeuroscienceRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Symeres and Ambagon collaborate for colorectal cancer moleculesNext: FDA points to liver injury with Amgen’s Tavneos Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
